Skip to search formSkip to main contentSkip to account menu

CEP-11981

Known as: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981 
An orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
SummaryBackground This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular… 
2014
2014
The balance between endothelial cell survival and death plays a pivotal role in brain remodeling and repair after stroke [1… 
2014
2014
BACKGROUND Angiopoietin/Tyrosine Kinase-2 (ANG/TIE2), Fibroblast Growth Factor-1 (FGFR1) and Vascular Endothelial Growth Factor… 
2012
2012
A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor… 
2009
2009
A hugyholyagrak a masodik leggyakrabban előfordulo urologiai jellegű tumoros megbetegedes. A mai gyakorlatban kezelesenek modjat… 
2007
2007
B264 The identification of novel anti-angiogenic agents with favorable drug-like properties and the ability to induce objective… 
2005
2005
The degree of angiogenesis in breast cancer has previously been shown to be an indicator of prognosis, and tumor microvasculature… 
Highly Cited
2003
Highly Cited
2003
Background—Angiopoietin (Ang)–1 is an angiogenic growth factor that counteracts the permeability and proinflammatory effects of… 
2003
2003
The degree of angiogenesis in breast cancer has previously been shown to be an indicator of prognosis, and tumor microvasculature… 
2001
2001
Activation of receptor tyrosine kinases by autophosphorylation is one of the most common and critical transformations in signal…